Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3: LY4268989 (MORF-057) in moderately to severely active ulcerative colitis
jRCT2051250259Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of LY4268989 in autoimmune colitis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of participants who achieve clinical remission with modified Mayo Score and Percentage of participants who achieve clinical remission with modified Mayo Score among participants who achieved clinical response with LY4268989 at Week 10. Started Jun 2026; status: recruiting.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2051250259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250259.